AUS
NZ
UK
CA
USA
IND
Healt
Singular Health Group (ASX:SHG) Maintains Strong Cash Runway for Growth
November 21, 2025 12:25 PM AEDT| By Team Kalkine MediaSingular Health Group maintains strong cash reserves, low debt, and strategic growth initiatives, positioning it well within the ASX 200 healthcare sector during periods of market volatility.
MedAdvisor (ASX:MDR) Revenue Struggles Limit ASX 200 Stock Prospects
November 21, 2025 11:48 AM AEDT| By SamMedAdvisor Limited (ASX:MDR) has low revenue growth and a modest P/S ratio. ASX 200 investors monitor performance relative to peers as the company works to improve its market outlook.
CSL Expansion Boosts US Operations: ASX Shares and Market Update
November 21, 2025 11:24 AM AEDT| By SamCSL (ASX:CSL) plans a $1.5 billion US expansion to boost immunoglobulin supply and manufacturing, with a focus on biologics, gene therapies, and operational efficiency amid market volatility.
Sonic Healthcare Faces Fresh Valuation Debate After Market Pullback
November 20, 2025 12:48 PM AEDT| By SamSonic Healthcare’s valuation draws renewed scrutiny as market conditions shift, inviting deeper assessment of its long-term demand, sector fundamentals and evolving strategic context within global healthcare.
Is the Market Misreading NYR as ASX 200 Sentiment Shifts?
November 20, 2025 12:25 PM AEDT| By SamNyrada experiences softer sentiment as ownership dynamics, biotechnology challenges and broader market themes shape perceptions, highlighting the gap between long-term scientific development and short-term market reactions.
Are SHL Shares Being Overlooked as ASX 200 Momentum Builds?
November 20, 2025 12:17 PM AEDT| By SamSonic Healthcare and Xero navigate shifting market sentiment while maintaining strong long-term positions within healthcare and digital finance, underscoring their continued relevance across Australia’s evolving economic landscape.
EMA backs PTX-100 breakthrough as Prescient Therapeutics advances beyond ASX 200
November 19, 2025 12:59 PM AEDT| By SamPrescient Therapeutics advances PTX-100 following orphan designation, strengthening its regulatory direction, clinical progress, and strategic development within targeted oncology, with continued focus on rare lymphoma conditions.
Breakthrough Cancer Screening Advances as BCAL Diagnostics Expands Reach
November 19, 2025 12:55 PM AEDT| By SamAustralia prepares for new blood-based cancer detection tools as BCAL advances clinical integration, expanded screening pathways, and telehealth support to strengthen early diagnostic access nationwide.
COG Financial Services Faces Market Pressure as Ownership Structure Shifts
November 19, 2025 11:59 AM AEDT| By SamCOG Financial Services experiences heightened attention as shifting ownership dynamics prompt fresh analysis. Public, institutional, insider, and private stakeholders collectively shape sentiment and long-term structural direction across the Australi...
All Ordinaries Spotlight on Proteomics International Laboratories and Its Biotech Funding Structure
November 18, 2025 04:27 PM AEDT| By SamExtensive assessment of funding utilisation, scientific operations and expenditure patterns for Proteomics International Laboratories within the All Ordinaries biotechnology sector.
Sonic Healthcare Limited Strengthens Diagnostic Capacity Across ASX 100 Healthcare Activity
November 18, 2025 04:13 PM AEDT| By SamExtensive analysis of Sonic Healthcare Limited’s diagnostic networks, laboratory capabilities, radiology services, scientific structure and wide-reaching role across major Australian healthcare indices.
CleanSpace Holdings and the All Ordinaries Amid a Shifting Commercial Equipment Landscape
November 17, 2025 05:09 PM AEDT| By SamCleanSpace Holdings’ recent operational update highlights themes surrounding manufacturing alignment, procurement cycles, and product distribution across safety-focused industries.
Recce Pharmaceuticals and the Evolving ASX 200 Landscape
November 17, 2025 01:16 PM AEDT| By SamRecce Pharmaceuticals reflects on the scientific legacy behind its technology platform, reinforcing its ongoing commitment to innovative anti-infective research within a dynamic Australian market landscape.
Bioxyne expands therapeutic footprint with new UK facility ASX 200
November 17, 2025 01:09 PM AEDT| By SamBioxyne expands its international therapeutic footprint through a new UK facility and evolving supply of regulated medicines, strengthening its presence across global alternative-treatment markets.
Race Oncology expands clinical programs with sector updates
November 17, 2025 01:06 PM AEDT| By SamRace Oncology expands programs in AML and lung cancer while progressing ongoing cardioprotection research and broader development planning.
Pro Medicus Moves Higher as Sector Interest Builds Across the ASX 200
November 17, 2025 11:53 AM AEDT| By SamPro Medicus gained early attention following a major enterprise contract, reinforcing confidence in cloud-based imaging solutions as broader ASX sectors observe steady engagement across technology, healthcare, and diversified market categories.
Trajan Group Holdings Faces Market Pressure Amid Shifting Sentiment ASX 200
November 17, 2025 10:54 AM AEDT| By SamTrajan Group Holdings navigates shifting market sentiment as observers reassess revenue momentum, sector context, and broader index movements influencing trade across the Australian market.
Pro Medicus Overview (ASX:PME) Across ASX 200 Healthcare Technology Landscape
November 14, 2025 06:47 PM AEDT| By SamExtensive overview of Pro Medicus, covering its enterprise imaging systems, workflow-technology operations, sector environment and representation across key ASX indices.
Australian Clinical Labs Overview (ASX:ACL) in the All Ordinaries Healthcare Landscape
November 14, 2025 06:35 PM AEDT| By SamAustralian Clinical Labs’ diagnostic operations, laboratory infrastructure, and sector activity, highlighting its position within the All Ordinaries index.
ASX 200 Update: Telix Pharmaceuticals (ASX:TLX) Drops as US Class Actions Mount
November 14, 2025 01:56 PM AEDT| By SamTelix Pharmaceuticals shares weakened after multiple US class actions alleged overstated progress on prostate cancer candidates and supply chain strength. The filings added pressure to a market already trading with softer sentiment.
Advertise your brand on Kalkine Media